<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="340">
  <stage>Registered</stage>
  <submitdate>27/01/2003</submitdate>
  <approvaldate>27/01/2003</approvaldate>
  <nctid>NCT00053092</nctid>
  <trial_identification>
    <studytitle>Combination Chemotherapy With or Without Rituximab in Treating Patients With Mantle Cell Lymphoma</studytitle>
    <scientifictitle>National Mantle Cell Lymphoma Trial - Phase II Randomized Study of Fludarabine/Cyclophosphamide Combination With or Without Rituximab in Patients With Untreated Mantle Cell Lymphoma</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>NCRI-LY05</secondaryid>
    <secondaryid>CDR0000269136</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Lymphoma</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Lymphoma (non Hodgkin's lymphoma) - High grade lymphoma</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Lymphoma (non Hodgkin's lymphoma) - Low grade lymphoma</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Other interventions - rituximab
Treatment: drugs - cyclophosphamide
Treatment: drugs - fludarabine phosphate

Other interventions: rituximab


Treatment: drugs: cyclophosphamide


Treatment: drugs: fludarabine phosphate


</interventions>
    <comparator />
    <control />
    <interventioncode>Other interventions interventions</interventioncode>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Response rate</outcome>
      <timepoint />
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Time to disease progression</outcome>
      <timepoint />
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Toxicity</outcome>
      <timepoint />
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Overall survival</outcome>
      <timepoint />
    </primaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>DISEASE CHARACTERISTICS:

          -  Histologically confirmed previously untreated mantle cell lymphoma requiring therapy

               -  Any stage

        PATIENT CHARACTERISTICS:

        Age

          -  18 and over

        Performance status

          -  Not specified

        Life expectancy

          -  At least 3 months

        Hematopoietic

          -  Not specified

        Hepatic

          -  Bilirubin no greater than 2.5 times upper limit of normal (ULN)^*

          -  Alkaline phosphatase no greater than 2.5 times ULN^*

          -  Hepatitis B and hepatitis C negative NOTE: *Unless related to lymphoma

        Renal

          -  Creatinine no greater than 2.5 times ULN^* NOTE: *Unless related to lymphoma

        Other

          -  No other malignancy within the past 5 years except non-melanoma skin cancer or
             curatively resected carcinoma in situ of the cervix

          -  No prior psychological illness or condition that would preclude study compliance

          -  No known hypersensitivity to murine proteins

          -  No concurrent uncontrolled medical conditions

          -  No other illness that would severely limit life expectancy

          -  HIV negative

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception during and for 6 months after study
             participation

        PRIOR CONCURRENT THERAPY:

        Biologic therapy

          -  Not specified

        Chemotherapy

          -  No prior chemotherapy

        Endocrine therapy

          -  Not specified

        Radiotherapy

          -  Not specified

        Surgery

          -  Not specified</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria />
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>1/10/2002</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>82</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/02/2009</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>VIC</recruitmentstate>
    <hospital>Peter MacCallum Cancer Centre - East Melbourne</hospital>
    <postcode>3002 - East Melbourne</postcode>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>England</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other</primarysponsortype>
    <primarysponsorname>Institute of Cancer Research, United Kingdom</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <othercollaborator>
      <othercollaboratortype>Other</othercollaboratortype>
      <othercollaboratorname>Australasian Leukaemia and Lymphoma Group</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing
      so they stop growing or die. Monoclonal antibodies such as rituximab can locate cancer cells
      and either kill them or deliver cancer-killing substances to them without harming normal
      cells. It is not yet known if combination chemotherapy is more effective with or without
      rituximab in treating mantle cell lymphoma.

      PURPOSE: Randomized phase II trial to compare the effectiveness of fludarabine and
      cyclophosphamide combined with rituximab to that of fludarabine and cyclophosphamide alone in
      treating patients who have mantle cell lymphoma.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00053092</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Simon Rule, MD</name>
      <address>Derriford Hospital</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>